Cargando…

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor

Etoposide is an anticancer agent, which is successfully and extensively used in treatments for various types of cancers in children and adults. However, due to the increases in survival and overall cure rate of cancer patients, interest has arisen on the potential risk of this agent for therapy-rela...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ezoe, Sachiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407914/ https://www.ncbi.nlm.nih.gov/pubmed/22851953 http://dx.doi.org/10.3390/ijerph9072444

Ejemplares similares

Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
por: Cowell, Ian G., et al.
Publicado: (2012)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Etoposide Quinone Is a Covalent Poison of Human Topoisomerase IIβ
por: Smith, Nicholas A., et al.
Publicado: (2014)

Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II
por: Le, Tung T., et al.
Publicado: (2023)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide
por: Sunter, Nicola J., et al.
Publicado: (2010)

Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
por: Vassetzky, Y. S., et al.
Publicado: (1996)

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
por: Okoro, Cosmas O., et al.
Publicado: (2023)

Changes in DNA methylation and transgenerational mobilization of a transposable element (mPing) by the Topoisomerase II inhibitor, Etoposide, in rice
por: Yang, Xuejiao, et al.
Publicado: (2012)

UPR-Induced Resistance to Etoposide Is Downstream of PERK and Independent of Changes in Topoisomerase IIα Levels
por: Mann, Melissa J., et al.
Publicado: (2012)

Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play
por: Zhang, Wenchao, et al.
Publicado: (2021)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
por: Ritke, M. K., et al.
Publicado: (1994)

Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences
por: Infante Lara, Lorena, et al.
Publicado: (2018)

Incidence of Mutation and Deletion in Topoisomerase IIα mRNA of Etoposide and mAMSA–resistant Cell Lines
por: Matsumoto, Yoshihito, et al.
Publicado: (2001)

Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II
por: Kuriappan, Jissy A., et al.
Publicado: (2019)

Hypophosphorylation of Topoisomerase IIα in Etoposide (VP‐16)‐resistant Human Carcinoma Cell Lines Associated with Carboxy‐terminal Truncation
por: Matsumoto, Yoshihito, et al.
Publicado: (2001)

Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
por: Smith, P. J., et al.
Publicado: (1994)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

QSAR Modeling on Benzo[c]phenanthridine Analogues as Topoisomerase I Inhibitors and Anti-cancer Agents
por: Thai, Khac-Minh, et al.
Publicado: (2012)

Natural Polyphenols as Modulators of Etoposide Anti-Cancer Activity
por: Kluska, Magdalena, et al.
Publicado: (2021)

Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
por: Asano, T., et al.
Publicado: (1996)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Protein Profiling of WERI-RB1 and Etoposide-Resistant WERI-ETOR Reveals New Insights into Topoisomerase Inhibitor Resistance in Retinoblastoma
por: Kakkassery, Vinodh, et al.
Publicado: (2022)

Altered expression of topoisomerase IIα contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation
por: Asano, T, et al.
Publicado: (2005)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

Synthesis and Biological Evaluation of New Pyridothienopyrimidine Derivatives as Antibacterial Agents and Escherichia coli Topoisomerase II Inhibitors
por: Mohi El-Deen, Eman M., et al.
Publicado: (2020)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

The Broken MLL Gene Is Frequently Located Outside the Inherent Chromosome Territory in Human Lymphoid Cells Treated with DNA Topoisomerase II Poison Etoposide
por: Glukhov, Sergey I., et al.
Publicado: (2013)

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
por: Michelson, Andrew P., et al.
Publicado: (2020)

Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy—An Overview
por: Salerno, Silvia, et al.
Publicado: (2022)

Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5’ splice site: Generation of etoposide resistance in human leukemia K562 cells
por: Hernandez, Victor A., et al.
Publicado: (2022)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT)
por: Kim, Hee Yeon, et al.
Publicado: (2021)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8bj0f8h3u4r3ef2orb7bfthjvv